Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lenvatinib Mesylate

FDA-approved product (capsule, oral), marketed as Lenvima.

Registered studies
23
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Lenvatinib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

23registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lenvatinib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lenvatinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

    NCT04008082 · start 2019-05-14

    Registered record
    Registry ID
    NCT04008082
    Conditions
    Carcinoma, Hepatocellular; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms
    Interventions
    Lenvatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-14
    Completion
    2022-01-28
    Enrolment
    412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms
    InterventionLenvatinib
    PhaseNot recorded
    Registry statusCompleted

  • Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

    NCT03477175 · start 2018-08-16

    Registered record
    Registry ID
    NCT03477175
    Conditions
    Solid Tumors
    Interventions
    E7080; Comparator Drug; Comparator Drug: Sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-08-16
    Completion
    2023-12-21
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionE7080; Comparator Drug; Comparator Drug: Sorafenib
    PhasePhase 2
    Registry statusCompleted

  • A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

    NCT03663114 · start 2018-07-02

    Registered record
    Registry ID
    NCT03663114
    Conditions
    Carcinoma, Hepatocellular
    Interventions
    Lenvatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-07-02
    Completion
    2020-02-20
    Enrolment
    713

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular
    InterventionLenvatinib
    PhaseNot recorded
    Registry statusCompleted

  • Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

    NCT02973997 · start 2018-02-07

    Registered record
    Registry ID
    NCT02973997
    Conditions
    Columnar Cell Variant Thyroid Gland Papillary Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Metastatic Thyroid Gland Follicular Carcinoma; Metastatic Thyroid Gland Papillary Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Follicular Carcinoma; Recurrent Thyroid Gland Papillary Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v7; Stage III Thyroid Gland Follicular Carcinoma AJCC v7; Stage III Thyroid Gland Papillary Carcinoma AJCC v7; Stage IV Thyroid Gland Follicular Carcinoma AJCC v7; Stage IV Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7; Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7; Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7; Stage IV
    Interventions
    Laboratory Biomarker Analysis; Lenvatinib; Lenvatinib Mesylate; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-02-07
    Completion
    2023-10-08
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColumnar Cell Variant Thyroid Gland Papillary Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma; Metastatic Thyroid Gland Follicular Carcinoma; Metastatic Thyroid Gland Papillary Carcinoma +16 more
    InterventionLaboratory Biomarker Analysis; Lenvatinib; Lenvatinib Mesylate; Pembrolizumab
    PhasePhase 2
    Registry statusCompleted

  • Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

    NCT02788708 · start 2016-05-27

    Registered record
    Registry ID
    NCT02788708
    Conditions
    Fallopian Tube Carcinoma; Recurrent Ovarian Cancer; Primary Peritoneal Carcinoma; Recurrent Endometrial Cancer
    Interventions
    Lenvatinib Mesylate; Paclitaxel; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05-27
    Completion
    2022-03-31
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFallopian Tube Carcinoma; Recurrent Ovarian Cancer; Primary Peritoneal Carcinoma; Recurrent Endometrial Cancer
    InterventionLenvatinib Mesylate; Paclitaxel; Pharmacological Study
    PhasePhase 1
    Registry statusCompleted

  • Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

    NCT02592356 · start 2015-11-16

    Registered record
    Registry ID
    NCT02592356
    Conditions
    Differentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma
    Interventions
    Computed Tomography; Dual X-ray Absorptiometry; Physical Examination; Quality-of-Life Assessment; Questionnaire Administration; Cabozantinib; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11-16
    Completion
    2024-03-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDifferentiated Thyroid Gland Carcinoma; Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Thyroid Gland Medullary Carcinoma
    InterventionComputed Tomography; Dual X-ray Absorptiometry; Physical Examination; Quality-of-Life Assessment +3 more
    PhaseNot applicable
    Registry statusCompleted

  • Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

    NCT02579616 · start 2015-10-23

    Registered record
    Registry ID
    NCT02579616
    Conditions
    Biliary Tract Cancer
    Interventions
    Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-10-23
    Completion
    2019-02-27
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Cancer
    InterventionLenvatinib
    PhasePhase 2
    Registry statusCompleted

  • Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

    NCT02430714 · start 2015-05-20

    Registered record
    Registry ID
    NCT02430714
    Conditions
    Thyroid Neoplasms
    Interventions
    Lenvatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05-20
    Completion
    2016-11-06
    Enrolment
    629

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Neoplasms
    InterventionLenvatinib
    PhaseNot recorded
    Registry statusCompleted